Helen H. Sun

GlaxoSmithKline (United States) — United States

Immunology and Microbiology · Life Sciences

9h-index997citations17works1.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

interferon and immune responses(7), Cell death mechanisms and regulation(6), Immune Response and Inflammation(3), Immune cells in cancer(2), NF-κB Signaling Pathways(2)

Publications17 total

Discovery of Isonitrile Lipopeptide Chalkophores from Pathogenic Mycobacteria
Journal of Natural Products·2025Open Access
Abstract 4236: Effects of a DNMT1-selective inhibitor on T-cell activity and tumor cells intrinsic pro-inflammatory response
Cancer Research·2025
Biosynthesis of isonitrile lipopeptides
Current Opinion in Chemical Biology·2024· 5 citedOpen Access
Understanding Pharmacokinetic Disconnect in Preclinical Species for 4-Aminoquinolines: Consequences of Low Permeability and High P-glycoprotein Efflux Ratio on Rat and Dog Oral Pharmacokinetics
Journal of Pharmaceutical Sciences·2020
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel
ACS Medicinal Chemistry Letters·2020· 4 citedOpen Access
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases
Journal of Medicinal Chemistry·2019· 65 citedOpen Access
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer
ACS Medicinal Chemistry Letters·2019· 79 citedOpen Access
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase
Journal of Medicinal Chemistry·2019· 68 citedOpen Access
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel
ACS Medicinal Chemistry Letters·2018· 35 citedOpen Access
Identification of an antibody‐based immunoassay for measuring direct target binding of <scp>RIPK</scp>1 inhibitors in cells and tissues
Pharmacology Research & Perspectives·2017· 9 citedOpen Access
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases
Journal of Medicinal Chemistry·2017· 464 citedOpen Access
The Identification and Pharmacological Characterization of 6-( <i>tert</i> -Butylsulfonyl)- <i>N</i> -(5-fluoro-1 <i>H</i> -indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase
Journal of Medicinal Chemistry·2016· 122 citedOpen Access
CCDC 1474873: Experimental Crystal Structure Determination
The Cambridge Structural Database·2016Open Access
Identification and characterization of potent, selective small molecule RIP2 kinase inhibitors (INM6P.422)
The Journal of Immunology·2014
Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis
ACS Medicinal Chemistry Letters·2013· 135 citedOpen Access
Functional Mapping of Bas2
Journal of Biological Chemistry·2002· 11 citedOpen Access
Subchronic and Chronic Toxicity of Tazarotene Gel Following Topical Application in Hanford Miniswine
International Journal of Toxicology·1997

Frequent Co-authors

Rakesh Nagilla(12), John Bertin(12), Peter J. Gough(11), Scott B. Berger(10), Michael Reilly(10), Elizabeth J. Rivera(10), Robert W. Marquis(10), Carol A. Capriotti(9), Michael T. Ouellette(9), Rachel D. Totoritis(8), Mukesh Mahajan(8), Joshua N. Finger(7), Pamela A. Haile(7), Bartholomew J. Votta(7), Barbara A. Swift(6), David B. Lipshutz(6), Biva M. Desai(6), Linda Casillas(6), Philip A. Harris(5), Bryan W. King(5)